Deals channel feed – Endpoints News

Deals channel feed

Defending its prize franchise, Vertex forks over $160M cash to grab Concert’s simplified version of Kalydeco

9 years ago

Otsuka Pharma snags a late-stage ADHD drug in $250M Neurovance buyout

9 years ago

How could you make a Bristol-Myers takeover work without shredding a $5B R&D division?

9 years ago

Buyout buzz swells for the giant Bristol-Myers after Carl Icahn makes an entrance, stage left

9 years ago

Sage CEO’s M&A chatter sparks a spike, and an awkward correction

9 years ago

Behind the scenes of J&J’s $30B Actelion buyout: Walkouts, Sanofi’s blunder and a $230M sweetener

9 years ago

The next PARP M&A deal? Tesaro shares surge on latest buzz about a buyout

9 years ago

Amgen rips off its $10B M&A cap, looking for deals “large and small”

9 years ago

Celgene scoops up freshman autoimmune startup Delinia in $775M buyout

9 years ago

J&J gets a $30B Actelion buyout and a new partner as Clozel’s team spins out with the pipeline

9 years ago

Novartis’ biotech shopping spree stays focused on the low-budget specials of the day

9 years ago

A biotech billionaire grabs microcap GenVec and its gene vector tech in buyout

9 years ago

How Takeda won a $5.2B bidding war — against itself

9 years ago

Anthrax-targeted biodefense biotechs join forces in merger pact

9 years ago

Eli Lilly nabs CoLucid and a PhIII migraine drug in $960M buyout

9 years ago

Pfizer wants you. And you. And you. And you.

9 years ago

Takeda grabs Ariad, expands oncology portfolio in $5.2B buyout

9 years ago

Celgene antes up $55M, grabs option to buy the autoimmune upstart Anokion

9 years ago

Savara jumping to the NYSE in reverse merger with zombie biotech Mast

9 years ago

The forecast for biotech IPOs in 2017? Not nearly as hot as the industry would like

9 years ago

Getting to work on pipeline construction, new Ipsen CEO forges $1B deal to buy Merrimack’s struggling Onivyde

9 years ago

M&A inflation just pushed the average biopharma valuation to a scary new peak

9 years ago

Shire spins out mRNA group to RaNA, which is hatching plans to tackle cystic fibrosis in the clinic

9 years ago

Make that two biotech reverse mergers in one day

9 years ago

First page Previous page 112 113 114115116 Next page Last page